ArticleCanadian liver journal2026
Blood donor hepatitis B data: An under-recognized surveillance resource in Canada.
Article in Canadian liver journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatitis B virus (HBV) infection surveillance is essential to gauge progress toward elimination, assess success identifying/treating cases, and evaluate prevention strategies. Canadian surveillance relies primarily on case detection. Data on undiagnosed HBV infection prevalence are limited. We explore the insight blood donors can bring to surveillance. Methods: Drawing upon the authors' expertise, operational knowledge, and published literature, we identified key topics to evaluate blood donor data. We then synthesized the relevant data and publications to propose unique insight gained from blood donor data. Results: Annually there are over 100,000 first-time donors; all are tested for anti-HBc, HBsAg, and HBV NAT. The infection rate (HBsAg- and/or NAT-positive) is about 70/100,000 donors, several-fold lower than general population estimates, and has decreased over the past two decades, consistent with an impact of vaccination programs and similar to the general population. Also similar to the general population, HBV infections are more common in Asian, Arab, and Black donors. There are a range of genotypes, with A and D more common in donors than in referred patients. Vaccine-age-eligible donors have lower chronic and resolved hepatitis B prevalence than vaccine-age-ineligible donors. Conclusions: Blood donors are an underutilized source of hepatitis B surveillance data that can lend unique insight into a low-risk population unlikely to be tested in clinical settings. Such data could supplement case detection surveillance. The impact of childhood vaccination programs is evident in adult blood donors. Blood donor residual specimens may be suitable for HBV vaccine-related serosurveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.